Therefore, adoption of tumour sequencing in LS screening pipelines may help overcome the previously highlighted barriers and limitations to MMR deficiency testing, specifically testing capacity, results interpretation, and reduced sensitivity due to MMR-proficient CRCs. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.